SCHEMBL254806

SCHEMBL254806

C#CCCC(=O)NCCCCCCC(C)C

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.43
CASP2 P42575 1/20 0.43
NAAA Q02083 1/20 0.41
ALDH1A1 P00352 2/20 0.41
NAMPT P43490 1/20 0.40
EPHX2 P34913 1/20 0.39
LMNA P02545 1/20 0.39
PKM P14618 1/20 0.39
CNR1 P21554 1/20 0.38
HPGD P15428 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDM4C Q9H3R0 2/20 0.36
KDM4A O75164 1/20 0.36
PHF8 Q9UPP1 1/20 0.36
KDM2A Q9Y2K7 1/20 0.36
FAAH O00519 1/20 0.36
EPHX1 P07099 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20113003 0.86 L3MBTL1 (0.40) L3MBTL1CASP2NAAAALDH1A1EPHX2
SCHEMBL10345306 0.83 NAMPT (0.52) CASP2NAAAALDH1A1NAMPTEPHX2
SCHEMBL10660707 0.83 NAMPT (0.52) CASP2NAAAALDH1A1NAMPTEPHX2
SCHEMBL22851659 0.83 ALDH1A1 (0.53) CASP2NAAAALDH1A1NAMPTLMNA
SCHEMBL16689691 0.83 ALDH1A1 (0.53) CASP2NAAAALDH1A1NAMPTLMNA
SCHEMBL24818366 0.83 NAMPT (0.52) CASP2NAAAALDH1A1NAMPTEPHX2
SCHEMBL18768756 0.83 ALDH1A1 (0.53) CASP2NAAAALDH1A1NAMPTLMNA
SCHEMBL10345059 0.83 NAMPT (0.52) CASP2NAAAALDH1A1NAMPTEPHX2
SCHEMBL18313728 0.82 ALDH1A1 (0.52) L3MBTL1CASP2NAAAALDH1A1NAMPT
SCHEMBL10051016 0.81 CASP2 (0.67) L3MBTL1CASP2NAAAEPHX2FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459565-B1 SAXITOXIN DERIVATIVES, METHODS AND COMPOSITIONS FOR STUDYING, IMAGING, AND TREATING PAIN UNIV LELAND STANFORD JUNIOR (US) 2018-05-02 EP disclosed
US-9174999-B2 Methods and compositions for studying, imaging, and treating pain THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2015-11-03 US disclosed
WO-2010129864-A9 METHODS AND COMPOSITIONS FOR STUDYING, IMAGING, AND TREATING PAIN THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2012-03-08 WO disclosed
US-20100284913-A1 Methods and compositions for studying, imaging, and treating pain THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO (US) 2010-11-11 US disclosed
WO-2010129864-A2 METHODS AND COMPOSITIONS FOR STUDYING, IMAGING, AND TREATING PAIN THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100284913-A1 Methods and compositions for studying, imaging, and treating pain INA, SCN3A, SCN9A L3MBTL1 3412/4885CASP2 3810/4885NAAA 873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.